BioSpace News Archive

Drug Development

Lilly Notches Second Cholesterol Win with RNA Silencer

At its highest dose level of 608 mg, lepodisiran reduced lipoprotein(a) levels by a median of 94% after 48 weeks.

November 13, 2023
·
2 min read
·
Tristan Manalac
Novartis Enters into Deal with Legend Biotech for $100 Million Upfront

After success with J&J, Legend strikes another license agreement, this one with Swiss pharma Novartis around CAR-T therapies.

November 13, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Atara Biotherapeutics’ Stock Plunges Following Phase II MS Trial Failure

The allogeneic T-cell immunotherapy company is now approaching penny stock territory after its multiple sclerosis drug failed to reach the primary endpoint in a mid-stage study.

November 13, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial

When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.

November 13, 2023
·
2 min read
·
Tristan Manalac
Business

Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines

The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.

November 13, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Aclaris’ Stock Crashes after Lead Asset Fails Mid-Stage Trial

Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II study for rheumatoid arthritis.

November 13, 2023
·
1 min read
·
Tyler Patchen
Drug Development

Novo Builds Wegovy’s Cardio Case with Much-Anticipated Data Drop

Novo Nordisk posted new data at AHA 2023 showing that its blockbuster weight loss drug could cut the risk of major cardiovascular events—including heart attack—across patient subgroups.

November 13, 2023
·
2 min read
·
Tristan Manalac
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines

ViaNautis Bio, a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to announce the successful completion of its Series A funding round, raising $25 million.

November 13, 2023
·
7 min read
Business

Biovica Signs Commercial Partner for the DiviTum(R) TKa Assay in the Nordics

Biovica International announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay.

November 13, 2023
·
2 min read
Drug Development

FluoGuide Announces FG001 Meets Primary Endpoint in Phase llb Trial in Aggressive Brain Cancer

FluoGuide A/S announced positive topline efficacy and safety results in the phase IIb trial with the lead product FG001 for guiding surgery in aggressive brain cancer.

November 13, 2023
·
4 min read